In vitro and In Vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Di Martino, Maria Teresa ^a,b   Gullà, Annamaria ^a   Cantafio, Maria Eugenia Gallo ^a   Altomare, Emanuela ^a   Amodio, Nicola ^a   Leone, Emanuela ^a   Morelli, Eugenio ^a   Lio, Santo Giovanni ^c   Caracciolo, Daniele ^a   Rossi, Marco ^a,b   Frandsen, Niels M ^d   Tagliaferri, Pierosandro ^a,b   Tassone, Pierfrancesco ^a,b,e  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b Oncologic Surgery   (Italy)

^c Internal Medicine   (Italy)

^d Exiqon AS   (Denmark)

^e Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EOSIN; HEMATOXYLIN; LOCKED NUCLEIC ACID; LOCKED NUCLEIC ACID INHIBITOR MICRORNA 221; MICRORNA 221; MICRORNA 222; PHOSPHOROTHIOIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BRDU ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NOD SCID MOUSE; NONHUMAN; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MICRORNAS; MOLECULAR TARGETED THERAPY; MULTIPLE MYELOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896119502     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089659     Document Type: Article

References (48)

1. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, et al. (2008) MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A 105: 12885-12890.
2. Chi J, Ballabio E, Chen XH, Kusec R, Taylor S, et al. (2011) MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct 6: 23.
3. Wu P, Agnelli L, Walker BA, Todoerti K, Lionetti M, et al. (2013) Improved risk stratification in myeloma using a microRNA-based classifier. Br J Haematol.
4. Corthals SL, Sun SM, Kuiper R, de Knegt Y, Broyl A, et al. (2011) MicroRNA signatures characterize multiple myeloma patients. Leukemia 25: 1784-1789.
5. Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, et al. (2009) Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 114: e20-26.
6. Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, et al. (2012) Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets 12: 838-846.
7. Thorsen SB, Obad S, Jensen NF, Stenvang J, Kauppinen S (2012) The therapeutic potential of microRNAs in cancer. Cancer J 18: 275-284.
8. Rossi M, Amodio N, Di Martino MT, Caracciolo D, Tagliaferri P, et al. (2013) From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario. Curr Drug Targets.
9. Misso G, Zappavigna S, Castellano M, De Rosa G, Di Martino MT, et al. (2013) Emerging pathways as individualized therapeutic target of multiple myeloma. Expert Opin Biol Ther 13 Suppl 1: S95-S109.
10. Amodio N, Di Martino MT, Neri A, Tagliaferri P, Tassone P (2013) Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. Expert Opin Biol Ther 13 Suppl 1: S125-137.
11. Dimopoulos K, Gimsing P, Gronbaek K (2013) Aberrant microRNA expression in multiple myeloma. Eur J Haematol 91: 95-105.
12. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, et al. (2012) Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 18: 6260-6270.
13. Amodio N, Di Martino MT, Foresta U, Leone E, Lionetti M, et al. (2012) miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis 3: e436.
14. Amodio N, Leotta M, Bellizzi D, Di Martino MT, D'Aquila P, et al. (2012) DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget 3: 1246-1258.
15. Di Martino MT, Gulla A, Cantafio ME, Lionetti M, Leone E, et al. (2013) In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget 4: 242-255.
16. Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, et al. (2013) Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res 19: 2096-2106.
17. Quintavalle C, Garofalo M, Zanca C, Romano G, Iaboni M, et al. (2012) miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPmu. Oncogene 31: 858-868.
18. Galardi S, Mercatelli N, Farace MG, Ciafre SA (2011) NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. Nucleic Acids Res 39: 3892-3902.
19. Zhang CZ, Zhang JX, Zhang AL, Shi ZD, Han L, et al. (2010) MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer 9: 229.
20. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, et al. (2010) miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A 107: 264-269.
21. Sredni ST, Bonaldo Mde F, Costa FF, Huang CC, Hamm CA, et al. (2010) Upregulation of mir-221 and mir-222 in atypical teratoid/rhabdoid tumors: potential therapeutic targets. Childs Nerv Syst 26: 279-283.
22. Mercatelli N, Coppola V, Bonci D, Miele F, Costantini A, et al. (2008) The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One 3: e4029.
23. Felicetti F, Errico MC, Bottero L, Segnalini P, Stoppacciaro A, et al. (2008) The promyelocytic leukemia zinc finger-microRNA-221/2222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 68: 2745-2754. (Pubitemid 351556272)
24. Hwang MS, Yu N, Stinson SY, Yue P, Newman RJ, et al. (2013) miR-221/222 Targets Adiponectin Receptor 1 to Promote the Epithelial-to-Mesenchymal Transition in Breast Cancer. PLoS One 8: e66502.
25. Jikuzono T, Kawamoto M, Yoshitake H, Kikuchi K, Akasu H, et al. (2013) The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma. Int J Oncol 42: 1858-1868.
26. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, et al. (2012) EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18: 74-82.
27. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, et al. (2009) miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16: 498-509.
28. Geary RS, Yu RZ, Levin AA (2001) Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs 2: 562-573. (Pubitemid 32401151)
29. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, et al. (2010) MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 328: 1566-1569.
30. Ng R, Song G, Roll GR, Frandsen NM, Willenbring H (2012) A microRNA-21 surge facilitates rapid cyclin D1 translation and cell cycle progression in mouse liver regeneration. J Clin Invest 122: 1097-1108.
31. Putta S, Lanting L, Sun G, Lawson G, Kato M, et al. (2012) Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol 23: 458-469.
32. Zarjou A, Yang S, Abraham E, Agarwal A, Liu G (2011) Identification of a microRNA signature in renal fibrosis: role of miR-21. Am J Physiol Renal Physiol 301: F793-801.
33. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, et al. (2010) miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 207: 1589-1597.
34. Boon RA, Seeger T, Heydt S, Fischer A, Hergenreider E, et al. (2011) MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ Res 109: 1115-1119.
35. Maegdefessel L, Azuma J, Toh R, Merk DR, Deng A, et al. (2012) Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J Clin Invest 122: 497-506.
36. Worm J, Stenvang J, Petri A, Frederiksen KS, Obad S, et al. (2009) Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF. Nucleic Acids Res 37: 5784-5792.
37. Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, et al. (2011) Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124: 1537-1547.
38. Grueter CE, van Rooij E, Johnson BA, DeLeon SM, Sutherland LB, et al. (2012) A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell 149: 671-683.
39. Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, et al. (2013) MicroRNA-34a regulates cardiac ageing and function. Nature 495: 107-110.
40. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, et al. (2013) Treatment of HCV infection by targeting microRNA. N Engl J Med 368: 1685-1694.
41. Lionetti M, Musto P, Di Martino MT, Fabris S, Agnelli L, et al. (2013) Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res 19: 3130-3142.
42. Burger R, Le Gouill S, Tai YT, Shringarpure R, Tassone P, et al. (2009) Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol Cancer Ther 8: 26-35.
43. Neri P, Tassone P, Shammas M, Yasui H, Schipani E, et al. (2007) Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma. Leukemia 21: 2519-2526. (Pubitemid 350148896)
44. Tassone P, Neri P, Burger R, Savino R, Shammas M, et al. (2005) Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res 11: 4251-4258. (Pubitemid 40791592)
45. Tassone P, Neri P, Carrasco DR, Burger R, Goldmacher VS, et al. (2005) A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 106: 713-716. (Pubitemid 40981270)
46. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. (Pubitemid 34164012)
47. Neri P, Tagliaferri P, Di Martino MT, Calimeri T, Amodio N, et al. (2008) In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol 143: 520-531.
48. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, et al. (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327: 198-201.